Cipla USA, Inc.

Cipla USA, Inc. (USA) has no DMF, CEP or site registration linked in our records. 24 FDA enforcement records are linked to it.

Sources: FDA Drug Master File list, EDQM certification database, FDA establishment registrations and enforcement records. How we read these records

Cite as: PharmaTek, “Cipla USA, Inc.: DMF, site and FDA enforcement record”, record as of 16 Nov 2026, pharmatek.co.uk/directory/cipla-usa-inc

Overview

Cipla USA, Inc. is a subsidiary of Cipla Limited, a global pharmaceutical company based in India. The company focuses on providing a wide range of pharmaceutical products, including generics and specialty drugs, to improve healthcare access in the United States.

Therapeutic areas

FDA compliance signals

24 FDA enforcement records linked to this company.

  • recall — Class II2026-10-14

    Failed Impurities/Degradation Specifications

  • recall — Class II2026-07-08

    cGMP Deviations: presence of N-nitroso-cinacalcet, above the acceptable daily intake (ADI).

  • recall — Class II2026-07-08

    cGMP Deviations: presence of N-nitroso-cinacalcet, above the acceptable daily intake (ADI).

  • recall — Class II2026-07-08

    cGMP Deviations: presence of N-nitroso-cinacalcet, above the acceptable daily intake (ADI).

  • recall — Class II2026-04-22

    CGMP Deviations; presence N-Nitroso Cinacalcet above the acceptable daily intake limit

  • recall — Class II2026-04-22

    CGMP Deviations; presence N-Nitroso Cinacalcet above the acceptable daily intake limit

  • recall — Class II2026-04-22

    CGMP Deviations; presence N-Nitroso Cinacalcet above the acceptable daily intake limit

  • recall — Class II2026-04-15

    Lack of Assurance of Sterility: Due to an FDA observation at the contract manufacturing site for deficiencies in their visual inspection procedure.

  • recall — Class II2026-04-15

    Lack of Assurance of Sterility: Due to an FDA observation at the contract manufacturing site for deficiencies in their visual inspection procedure.

  • recall — Class III2026-03-11

    Failed Tablet/Capsule Specifications: Observed OOS results at 6-months long-term stability condition for Description test and Appearance by Visual Inspection test.

  • recall — Class III2026-03-11

    Failed Tablet/Capsule Specifications: Observed OOS results at 6-months long-term stability condition for Description test and Appearance by Visual Inspection test.

  • recall — Class III2026-01-28

    Failed PH Specifications

  • recall — Class II2026-01-21

    Presence of Particulate Matter.

  • recall — Class II2025-12-17

    CGMP Deviations: the presence of a nitrosamine impurity, N-nitroso-cinacalcet, above the acceptable daily intake (ADI) limits.

  • recall — Class II2025-12-17

    Failed stability specifications: Out of specification for hardness test

  • recall — Class II2025-12-17

    CGMP Deviations: the presence of a nitrosamine impurity, N-nitroso-cinacalcet, above the acceptable daily intake (ADI) limits.

  • recall — Class II2025-12-17

    Failed stability specifications: Out of specification for hardness test

  • recall — Class II2025-12-17

    CGMP Deviations: the presence of a nitrosamine impurity, N-nitroso-cinacalcet, above the acceptable daily intake (ADI) limits.

  • recall — Class III2025-08-27

    Failed Stability Specifications: Out of specification results was observed in Induction Port during the analysis of Particle size distribution at the 12-month time point.

  • recall — Class II2025-07-30

    Lack of Assurance of Sterility: A market complaint was received for leakage and empty ampoule.

  • recall — Class II2024-11-20

    Failed Tablet/Capsule Specifications: Complaints received of crushed and broken tablets.

  • recall — Class II2024-11-20

    Failed Tablet/Capsule Specifications: Complaints received of crushed and broken tablets.

  • recall — Class II2024-05-01

    Short fill: Complaints received of less fill volume in respule and few drops of liquid observed in the intact pouch.

  • recall — Class I2023-07-19

    Defective container: empty inhaler and leakage observed through the inhaler valve due to partially missing bottom seat (gasket).

For suppliers

Is this Cipla USA, Inc.?

Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.

Free. Payment never buys an evidence status.

Need suppliers found and checked?

The Sourcing Desk turns these records into a checked shortlist: current filings, site, grade and regulatory history confirmed for your product, for a buyer-paid fixed fee and no supplier commission.